Human Leucine-rich repeat-containing G-protein coupled receptor 5(LGR5) ELISA kit

Instructions
Code CSB-EL012906HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name leucine-rich repeat-containing G protein-coupled receptor 5
Alternative Names FEX ELISA Kit; G protein coupled receptor 49 ELISA Kit; G protein coupled receptor 67 ELISA Kit; g protein-coupled receptor fex ELISA Kit; G-protein coupled receptor 49 ELISA Kit; G-protein coupled receptor 67 ELISA Kit; G-protein coupled receptor HG38 ELISA Kit; GPCR GPR49 ELISA Kit; GPR 49 ELISA Kit; GPR 67 ELISA Kit; GPR49 ELISA Kit; GPR67 ELISA Kit; GRP 49 ELISA Kit; GRP49 ELISA Kit; HG 38 ELISA Kit; HG38 ELISA Kit; Leucine rich repeat containing G protein coupled receptor 5 ELISA Kit; Leucine-rich repeat-containing G-protein coupled receptor 5 ELISA Kit; LGR 5 ELISA Kit; LGR5 ELISA Kit; LGR5_HUMAN ELISA Kit; MGC117008 ELISA Kit; Orphan G protein coupled receptor HG38 ELISA Kit
Abbreviation LGR5
Uniprot No. O75473
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates, cell lysates
Detection Range 18.75 pg/mL-1200 pg/mL
Sensitivity 4.69 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cancer
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human LGR5 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 98
Range % 91-102
1:2 Average % 89
Range % 81-94
1:4 Average % 97
Range % 88-101
1:8 Average % 102
Range % 92-107
Recovery
The recovery of human LGR5 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 95 85-100
EDTA plasma (n=4) 102 94-107
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
1200 1.882 1.943 1.913 1.733
600 1.559 1.576 1.568 1.388
300 1.080 1.139 1.110 0.930
150 0.817 0.802 0.810 0.630
75 0.515 0.531 0.523 0.343
37.5 0.392 0.384 0.388 0.208
18.75 0.293 0.289 0.291 0.111
0 0.182 0.178 0.180  
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 7-14 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Receptor for R-spondins that potentiates the canonical Wnt signaling pathway and acts as a stem cell marker of the intestinal epithelium and the hair follicle. Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signaling pathway to increase expression of target genes. In contrast to classical G-protein coupled receptors, does not activate heterotrimeric G-proteins to transduce the signal. Involved in the development and/or maintenance of the adult intestinal stem cells during postembryonic development.
Gene References into Functions
  1. Data conclude that LGR5 expression in CTCs may serve as a marker for CRC metastasis. PMID: 29949050
  2. LGR5 is a new functional GSC marker and prognostic indicator that can promote EMT by activating the Wnt/beta-catenin pathway and would thus be a novel therapeutic target for glioma. PMID: 30208924
  3. Data found LGR5 as a potential target of miR-340. LGR5 was highly expressed in breast cancer cells. Relative expression of LGR5 was negatively regulated by miR-340. Knockdown of LGR5 also inhibited cell proliferation and drug resistance to docetaxel with enhanced cell apoptosis of breast cancer cells. PMID: 30300682
  4. knockdown of CASC15 significantly inhibited the proliferation, migration and invasion of colon cancer cells in vitro and in vivo. Following mechanistic experiments, CASC15 was observed to act as a sponge to suppress microRNA (miR)4310 that targeted LGR5. PMID: 29956772
  5. LGR5 overexpression was associated with high T stage and LN metastasis status in breast cancer. High LGR5 expression was also associated with reduced relapse-free survival, indicating that LGR5 may represent a promising prognostic marker for breast cancer patients. PMID: 29471794
  6. LGR5 is a critical effector of DDX1 in colorectal cancer cells. PMID: 29869821
  7. Logarithmic expansion of LGR5-expressing cells was observed in human colorectal cancer. PMID: 28958617
  8. Our findings indicated that the Lgr5High/DCLK1High expression pattern may be considered as a signature phenotype for intestinal subtypes of gastric carcinoma. PMID: 28946555
  9. Findings suggest a tumor suppressor role for miR-216a in gliomas, which inhibits glioma cell proliferation, migration, and invasion by targeting LGR5. PMID: 28256193
  10. LGR5 promotes cancer stem cell traits and chemoresistance in cervical cancer. PMID: 28880275
  11. LGR5 expression in the epithelium and stroma was associated with tumor stage, and by integrating functional experiments with LGR5-sorted cell RNA sequencing data from adenoma and normal organoids, there were correlations between LGR5 and CRC-specific genes, including dickkopf WNT signaling pathway inhibitor 4 (DKK4) and SPARC-related modular calcium binding 2 (SMOC2 PMID: 29467240
  12. LGR5 expression is transiently upregulated during the early stage of cardiomyocyte differentiation from hPSCs, and although LGR5 expression is not required for maintaining hPSCs in the undifferentiated state, knockdown of LGR5 leads to decreased expression of key cardiac transcription factors at the early stage with eventual lack of robust beating cardiomyocytes at the late stage. PMID: 28793247
  13. Lgr5 plays important roles in angiogenesis. Lgr5-specific siRNA could be designed into an effective therapeutic agent to inhibit gastric cancer angiogenesis. PMID: 28404940
  14. A regulatory mechanism of LGR5 expression in gastric carcinogenesis, with SP1 as an important component of the transcriptional complex and LGR5 activity, which is modulated by its ligands RSPO1 and RSPO2, whose expression is modulated by methylation. PMID: 28219935
  15. these results demonstrate that Lgr5 activation of Wnt/beta-catenin signaling is a potential mechanism to promote the progression of ESCC and ESCC stem cell renewal, and Lgr5 may be used as a molecular target for the development of treatments for ESCC. PMID: 28404917
  16. This study uncovers a novel cross-talk between LGR5 and TGFbeta signaling in colon cancer and identifies LGR5 as a new modulator of TGFbeta signaling able to suppress colon cancer metastasis. PMID: 28939678
  17. Data show that IKKalpha directly bind to the promoters of LGR5, in turn, upregulating LGR5 expression through activation of STAT3 signaling pathway during cancer progression. PMID: 27049829
  18. Report the presence of aberrantly located LGR5(+) cells coexpressing epithelial markers in the stromal compartment of women with endometriosis. These cells have a statistically significantly different expression profile in deep-infiltrating endometriosis in comparison with other types of endometriosis, independent of the menstrual cycle phase. PMID: 28923287
  19. Arrb1 reduced the chemotherapy-induced Lgr5 stem cell apoptosis by inhibiting endoplasmic reticulum stress-mediated mitochondrial apoptotic signaling. PMID: 27195676
  20. LGR5 signaling in gastric cancer cells.LGR5 crosstalk with FOXO1 in gastric cancer cells. PMID: 28970066
  21. High LGR5 expression is associated with osteoarthritis. PMID: 28777797
  22. The LGR5 primarily functions via the IQGAP1-Rac1 pathway to strengthen cell-cell adhesion in normal adult crypt stem cells and colon cancer cells. PMID: 28739799
  23. Lgr5(+) chief cells are involved in maintaining the homeostatic stem cell pool. Define Lgr5(+) chief cells as a major cell-of-origin of gastric cancer. PMID: 28581476
  24. LGR5-expressing fraction of CD54+ cells represents gastric cancer CSCs, in which LGR5 is closely associated with stemness and EMT core genes PMID: 28033430
  25. clathrin-mediated endocytosis inhibition of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness PMID: 28275053
  26. The findings indicated that Lgr5 might contribute to the intestinal metaplasia during gastric carcinogenesis. PMID: 26077638
  27. Endometrial LGR5 is not an endogenous stem cell marker. Instead, LGR5(+) cells appear to be recruited from blood to be part of the stem cell niche at the perivascular microenvironment to activate the endogenous niche. PMID: 27887719
  28. 2 LGR5 splice variants were expressed in human intestine crypt cells; one lacked exon 5 and the other lacked exons 5-8. Only LGR5FL appeared during cell cycle arrest. The transcript variants appeared when the cell cycle was proceeding. LGR5FL-positive cells were negative for Ki-67 and were enriched after chemotherapy. PMID: 27140312
  29. Low expression of LGR5 is associated with gastric cancer. PMID: 26386561
  30. Report targeting LGR5+ tumor stem cells with an antibody-drug conjugate as effective treatment for colon cancer. PMID: 26582901
  31. Lgr5 overexpression was significantly associated with deep invasion of colorectal cancer lymphnode metastasis, distant metastasis and AJCC stage PMID: 26758198
  32. Data suggest that targeting of leucine rich repeat containing G protein-coupled receptor 5 (LGR5) may be of therapeutic benefit for neuroblastomas. PMID: 26517508
  33. This study shows that Lgr5 can be a valuable and reliable prognostic factor of colorectal cancer progression. PMID: 26674601
  34. We conclude that overexpression of LGR5 is associated with markers of tumor aggressiveness in human papillary thyroid cancer PMID: 26416247
  35. The results suggest that trichosanthin may induce apoptosis in glioma cells by targeting LGR5 and repressing the Wnt/betabcatenin signaling pathway PMID: 26397053
  36. These findings indicate that LGR5 not only participates in carcinogenesis but also maintained stemness by activating Wnt/b-catenin signaling in breast cancer. PMID: 26086949
  37. We confirmed in a large and independent study cohort that LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-FU-based adjuvant chemotherapy. PMID: 25665511
  38. lgr5 methylation, through the regulation of lgr5 expression and colorectal CSC differentiation, may constitute a novel prognostic marker for colorectal cancer patients. PMID: 26599100
  39. High resolution crystal structure of an ectodomain variant of human LGR5 (hLGR5ecto) complexed with a signalling competent fragment of mouse Rspo2. PMID: 26123262
  40. Lgr5-positive cells may be cancer stem cells-like cells in gastric cancer. PMID: 26279446
  41. Demonstrate the presence of LGR5-positive cells in limbal epithelial crypts and their decrease in inflamed conditions, which suggests a critical role of this protein during inflammation and its possible use as a marker in normal crypts. PMID: 26097379
  42. Elevated Lgr5 expression might contribute to the development and progression of colorectal cancer. PMID: 24751002
  43. data reveal a RSPO2-induced, LGR5-dependent Wnt signaling-negative feedback loop that exerts a net growth-suppressive effect on CRC cells PMID: 24476626
  44. our data highlight a potential role of Lgr5-positive cells in the tumorigenesis of colorectal cancer (CRC), and suggest that treating these Lgr5-positive cells in CRCs may substantially improve the outcome of CRC therapy PMID: 25835970
  45. Lgr5 may play an important role in the development and progression of cervical carcinoma. PMID: 25973068
  46. Based on the lack of correlation between Lgr5 and tested cancer stem cell markers, Lgr5 does not seem to be a potential stemness marker or prognostic factor in pancreatic ductal adenocarcinoma. PMID: 25804119
  47. High LGR5 expression was associated with poor prognosis in patients with colorectal cancer(CRC) and that LGR5 is an efficient prognostic factor in CRC. [meta-analysis; review] PMID: 25192390
  48. we suggest that Musashi-1, Lgr5, and pEGFR are overexpressed in human SIAs and may play roles in human SIA carcinogenesis and progression. PMID: 25773390
  49. the higher expression level of DCLK1 in patients undergoing CRT can propose it as a more relevant candidate among CSC markers comparing to Lgr5 for colorectal cancer patients. PMID: 25631749
  50. increased expression of LGR5 during embryogenesis and the neonatal period alter skin development and homeostasis. PMID: 26003047

Show More

Hide All

Subcellular Location Cell membrane, Multi-pass membrane protein, Golgi apparatus, trans-Golgi network membrane, Multi-pass membrane protein
Protein Families G-protein coupled receptor 1 family
Tissue Specificity Expressed in skeletal muscle, placenta, spinal cord, and various region of brain. Expressed at the base of crypts in colonic and small mucosa stem cells. In premalignant cancer expression is not restricted to the cript base. Overexpressed in cancers of th
Database Links

HGNC: 4504

OMIM: 606667

KEGG: hsa:8549

STRING: 9606.ENSP00000266674

UniGene: Hs.658889

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1